Generic versions of a groundbreaking injectable HIV-prevention drug should be available for $40 a year in more than 100 ...

Approved in June for people at high risk of HIV, Yeztugo was shown to be nearly 100% effective at preventing infection in large trials.

Research published in The Lancet HIV earlier this year, experts estimated that, if purchased at scale, the cost of generic lenacapavir could range from USD 35 to USD 46 per person-year. Falling to USD ...

Global health groups will provide backing for two generic manufacturers to produce and distribute a low-cost version of a new HIV prevention drug in poor countries.

Indian drugmakers Dr Reddy's Laboratories and Hetero Labs said on Wednesday that they will sell generic versions of a new and ...

Gilead stock toppled Thursday after CVS HealthCVS said it won't add the company's new HIV prevention drug, Yeztugo, to its commercial plans for now. The decision is based on clinical, financial and ...

Two partnerships will provide millions of people access to what is widely described as the most effective HIV prevention drug ...

Lupin's shares surged by 2.2% following tentative U.S. FDA approval for its generic HIV treatment, Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets. This positions Lupin to enter a ...

CVS Health Inc. CVS said it will not add Gilead Sciences Inc.’s GILD new HIV prevention drug Yeztugo to its commercial plans. In June, the U.S. Food and Drug Administration (FDA) approved Gilead ...

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

Florida will get $3 million as part of a nationwide settlement over allegations a drug manufacturer gave kickbacks to doctors.

(Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite ...